Parametric Portfolio Associates LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 79,654 shares of the biopharmaceutical company’s stock, valued at approximately $928,000. Parametric Portfolio Associates LLC owned approximately 0.14% of TG Therapeutics as of its most recent filing with the SEC.
A number of other large investors have also recently modified their holdings of TGTX. Ameriprise Financial Inc. purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $1,291,000. Swiss National Bank raised its stake in shares of TG Therapeutics by 18.9% in the first quarter. Swiss National Bank now owns 79,200 shares of the biopharmaceutical company’s stock worth $923,000 after buying an additional 12,600 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of TG Therapeutics by 40.7% in the first quarter. Bank of New York Mellon Corp now owns 271,879 shares of the biopharmaceutical company’s stock worth $3,168,000 after buying an additional 78,644 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $16,034,000. Finally, North Star Investment Management Corp. raised its stake in shares of TG Therapeutics by 110.0% in the first quarter. North Star Investment Management Corp. now owns 21,000 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 11,000 shares in the last quarter. Hedge funds and other institutional investors own 46.53% of the company’s stock.
Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) traded down 1.36% during mid-day trading on Friday, hitting $10.85. The company’s stock had a trading volume of 889,366 shares. The stock has a 50-day moving average of $10.91 and a 200-day moving average of $10.23. TG Therapeutics, Inc. has a 12-month low of $4.10 and a 12-month high of $15.35. The company’s market cap is $676.06 million.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. On average, equities research analysts forecast that TG Therapeutics, Inc. will post ($1.84) EPS for the current year.
A number of brokerages recently commented on TGTX. Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research report on Saturday, June 17th. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $23.67.
In related news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the sale, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at $5,295,075.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 16.70% of the stock is owned by company insiders.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.